Skip to main content
. Author manuscript; available in PMC: 2014 Jul 24.
Published in final edited form as: Cancer Res. 2007 Jul 1;67(13):6174–6182. doi: 10.1158/0008-5472.CAN-06-3455

Figure 4.

Figure 4

Depletion of BCAR3 in MDA-MB-231 or BT549 cells results in reduced migration and invasion. A, MDA-MB-231 and BT549 cells were treated with vehicle (H2O; lanes 1 and 4 ), nontargeting siRNAs (lanes 2 and 5 ), or BCAR3-specific siRNAs (lanes 3 and 6). Forty-eight hours later, cells were lysed and 50 μg total cell lysate were immunoblotted for BCAR3 (top panels) and GAPDH (bottom panels). B, vehicle-treated (black columns), control siRNA–treated (gray columns), or BCAR3-specific siRNA–treated (white columns) MDA-MB-231 and BT549 cells were seeded onto Boyden chambers 48 h posttransfection and allowed to migrate toward 10% serum for 6 h. C, vehicle-treated (black columns), control siRNA–treated (gray columns), or BCAR3-specific siRNA–treated (white columns) MDA-MB-231 and BT549 cells were seeded onto Matrigel-coated Boyden chambers 48 h posttransfection and allowed to migrate toward 10% serum for 24 h. Columns (B and C), mean for eight independent experiments; bars, SD. *, P < 0.05 relative to both vehicle siRNA and control siRNA treatment of cells.